Disease-modifying treatments for multiple sclerosis - a review of approved medications
about
Imaging as an Outcome Measure in Multiple Sclerosis.Psychometric properties of the SDM-Q-9 questionnaire for shared decision-making in multiple sclerosis: item response theory modelling and confirmatory factor analysisAdherence to disease-modifying therapies and its impact on relapse, health resource utilization, and costs among patients with multiple sclerosis.GYF-21, an Epoxide 2-(2-Phenethyl)-Chromone Derivative, Suppresses Innate and Adaptive Immunity via Inhibiting STAT1/3 and NF-κB Signaling PathwaysUsing a multidimensional unfolding approach to assess multiple sclerosis patient preferences for disease-modifying therapy: a pilot study"Cure" for multiple sclerosis (MS)-Evolving views of therapy goals in patients on different stages of the disease: A pilot study in a cohort of Polish MS patientsThe Use of Immunosuppressant Therapy for Multiple Sclerosis in Italy: A Multicenter Retroprospective Study.The Efficacy of Natalizumab versus Fingolimod for Patients with Relapsing-Remitting Multiple Sclerosis: A Systematic Review, Indirect Evidence from Randomized Placebo-Controlled Trials and Meta-Analysis of Observational Head-to-Head Trials.Perspectives and experiences of Dutch multiple sclerosis patients and multiple sclerosis-specialized neurologists on injectable disease-modifying treatment.Glatiramer acetate attenuates the activation of CD4+ T cells by modulating STAT1 and -3 signaling in glia.High-dose immunosuppressive therapy and autologous HCT for relapsing-remitting MS.Conjoint analysis to understand preferences of patients with multiple sclerosis for disease-modifying therapy attributes in Spain: a cross-sectional observational studySystematic literature review and network meta-analysis in highly active relapsing-remitting multiple sclerosis and rapidly evolving severe multiple sclerosis.An update on cladribine for relapsing-remitting multiple sclerosis.Patient satisfaction with ExtaviPro™ 30G, a new auto-injector for administering interferon β-1b in multiple sclerosis: results from a real-world, observational EXCHANGE study.Development of Glatopa® (Glatiramer Acetate): The First FDA-Approved Generic Disease-Modifying Therapy for Relapsing Forms of Multiple Sclerosis.Thiazolidinedione drugs in the treatment of type 2 diabetes mellitus: past, present and future.Single-cell profiling reveals GPCR heterogeneity and functional patterning during neuroinflammation.Adherence to disease-modifying therapies for multiple sclerosis and subsequent hospitalizations.The future of multiple sclerosis treatments.Treatment-Related Progressive Multifocal Leukoencephalopathy in Multiple Sclerosis: A Comprehensive Review of Current Evidence and Future Needs.Current and Emerging Therapies in Multiple Sclerosis: Implications for the Radiologist, Part 1-Mechanisms, Efficacy, and Safety.Survival and cause of death in multiple sclerosis: a 60-year longitudinal population study.Dietary Interventions and Multiple Sclerosis.Nogo-A Antibodies for Progressive Multiple Sclerosis.The Italian Pharmacovigilance Program: An Observational Study of Adverse Effects of Natalizumab in Multiple Sclerosis Therapy.Impact on healthcare resource utilization of multiple sclerosis in Spain.A Systems Medicine Approach Reveals Disordered Immune System and Lipid Metabolism in Multiple Sclerosis Patients.Comparison of preferences of healthcare professionals and MS patients for attributes of disease-modifying drugs: A best-worst scaling.To the Brain and Back: Migratory Paths of Dendritic Cells in Multiple Sclerosis.Relapse outcomes, safety, and treatment patterns in patients diagnosed with relapsing-remitting multiple sclerosis and initiated on subcutaneous interferon β-1a or dimethyl fumarate: a real-world study.Alemtuzumab Improves Cognitive Processing Speed in Active Multiple Sclerosis-A Longitudinal Observational Study.Efficacy of alemtuzumab and natalizumab in the treatment of different stages of multiple sclerosis patients.Persistence to oral disease-modifying therapies in multiple sclerosis patients.Optimal response to dimethyl fumarate associates in MS with a shift from an inflammatory to a tolerogenic blood cell profile.Inflammation in CNS Neurodegenerative Diseases.Establishing pathological cut-offs for lateral ventricular volume expansion rates.Tolerogenic Nanoparticles Induce Antigen-Specific Regulatory T Cells and Provide Therapeutic Efficacy and Transferrable Tolerance against Experimental Autoimmune Encephalomyelitis.Identification of brain antigens recognized by autoantibodies in experimental autoimmune encephalomyelitis-induced animals treated with etomoxir or interferon-β.Inhibition of Inflammation, Suppression of Matrix Metalloproteinases, Induction of Neurogenesis, and Antioxidant Property Make Bryostatin-1 a Therapeutic Choice for Multiple Sclerosis.
P2860
Q31134617-1A685D8F-BF1D-4C0C-92E9-0973B325F2D8Q33592524-3756360A-4AB2-4865-A104-BE911A6A3984Q33638157-A2BBD124-E0DA-4B58-9EE3-B120217C82E4Q33710758-87AD9C81-239D-4664-9358-A25861EC41BAQ33768847-A3E3235C-7CF9-4DA0-BE5F-C65D8A329023Q33810097-CBF64D10-DCCC-496C-B5E2-0E8BF47A7515Q36062456-5D93FD46-6577-4574-AE03-8AF74F4A83DEQ36148189-5DC60DCA-44F9-4E47-9750-46F59261DB27Q36861884-E680808A-AED2-4563-BBCD-9B9E687506D2Q37589284-D8B3F264-6A7E-424B-B7DE-21AEDDD3B373Q37673801-7C021345-CC9D-4DF7-AE56-F1DA686C3416Q37704257-B5C3052C-2A05-4FE2-B9F2-E9F5A6FF0061Q37704322-B9B7B9C3-C733-4C15-BB18-4677BB1B91EEQ38600051-E8C3892A-7A67-4A17-BE84-13A886AE83ABQ38631863-7F415231-F14A-4EE4-86A7-7A05FBEF8E6AQ38636620-C34A6B63-031A-46F2-90C2-8B890FE25BBBQ38641190-25928D1D-7985-40B2-90B8-24639CA1F60AQ38645945-E251310C-F43D-4F5B-BF46-ED18F424FB91Q38735869-0A12E5B4-C519-4445-ABD3-96A65862B2EFQ38808485-3F9F0765-32AA-4959-9085-5DA5D7B20A84Q38815391-E04C45ED-63E4-4C35-BB09-522C8CA86122Q38837567-A67F3961-A33A-49DB-9F4C-51393BA0473BQ38862639-9AFAD33C-70BB-499B-BDCC-2BBB15ECD8DEQ38895161-F1666881-9C27-44BB-9A07-288372453EBDQ39010894-50062602-6349-41F1-81FD-4CD743AFAD2AQ41381386-B914E9DE-2D1F-4810-9810-8C66B8301770Q47094353-15C73250-15D7-4DDA-A7D3-C6A16AB6E0C6Q47342256-637DE938-6B37-4B03-B03F-72FC69FC116EQ47663169-D894690D-9E98-4149-B4EB-841D23FB6AE9Q47859915-0E3ADCCC-B2FC-4004-9E63-0EF813ADBFA4Q47986992-3D35FCDD-5240-4EB2-9E08-D068116EAAAFQ49539768-0CE151CC-24AF-45DD-A49F-8F46601F11D5Q49712050-04147633-6AEC-4B9C-BDA6-DD52B80FC6D2Q50498068-3DF83318-127B-49FB-972C-7E9454E2A073Q50577568-15E89415-089F-4FEE-A656-7BFEE57D9619Q51765219-2B6C7690-599F-4C64-81C1-144FAAA98E55Q52661563-EE4E2590-361C-4C96-936E-ABBF8E7C827DQ55049471-F7C9D418-3467-47E0-B5ED-19BA61552A0AQ55187995-166A9BC1-42C3-48F4-A0AA-4B251D216532Q55483693-AF34F36E-DA5A-4099-AA19-B2BC66FDAF67
P2860
Disease-modifying treatments for multiple sclerosis - a review of approved medications
description
2016 nî lūn-bûn
@nan
2016 թուականի Յունուարին հրատարակուած գիտական յօդուած
@hyw
2016 թվականի հունվարին հրատարակված գիտական հոդված
@hy
2016年の論文
@ja
2016年論文
@yue
2016年論文
@zh-hant
2016年論文
@zh-hk
2016年論文
@zh-mo
2016年論文
@zh-tw
2016年论文
@wuu
name
Disease-modifying treatments for multiple sclerosis - a review of approved medications
@ast
Disease-modifying treatments for multiple sclerosis - a review of approved medications
@en
Disease-modifying treatments for multiple sclerosis - a review of approved medications
@nl
type
label
Disease-modifying treatments for multiple sclerosis - a review of approved medications
@ast
Disease-modifying treatments for multiple sclerosis - a review of approved medications
@en
Disease-modifying treatments for multiple sclerosis - a review of approved medications
@nl
prefLabel
Disease-modifying treatments for multiple sclerosis - a review of approved medications
@ast
Disease-modifying treatments for multiple sclerosis - a review of approved medications
@en
Disease-modifying treatments for multiple sclerosis - a review of approved medications
@nl
P2860
P921
P3181
P356
P1476
Disease-modifying treatments for multiple sclerosis - a review of approved medications
@en
P2860
P3181
P356
10.1111/ENE.12883
P407
P478
23 Suppl 1
P5008
P577
2016-01-01T00:00:00Z